Tree of Knowledge International Corp. (CSE:TOKI; OTC:TRKWF) (the “Company” or “TOK”) (formerly Courtland Capital Inc.) is pleased to announce that world-renowned Dr. Sanjay Gupta has joined its world class Advisory Board.

Dr. Sanjay Gupta


Dr. Sanjay Gupta is perhaps one of the most well-known medical professionals worldwide, and is one of the most recognized and influential leaders in his field.  In addition to serving as President of DrCircle.com, he has appeared on various television platforms and as the Director of Health Time TV, comprised of more than 160,000 medical professionals. He is a Harvard trained pain specialist and President of the American Pain Association, as well as an outspoken proponent of medical marijuana and it’s role in fighting the opioid epidemic. He has received several awards including Top Docs Awards, Michiganian of the Year Award and Best resident physician Award.

Dr. Gupta joins Dr. Michael Smatt, Joy Beckerman, Christopher Kaplan and Ambassador Jack Brewer on the Company’s Advisory Board.   The mandate of the Advisory Board is to serve as a strategic resource for the Company to advise on healthcare outreach initiatives surrounding CBD and the furtherance of educating both patients and athletes and support the Company’s overall mission.

Michael Caridi, Chairman and CEO of the Company stated:  “We have truly built a world class advisory board with the addition of Dr. Sanjay Gupta.  His leadership, knowledge and influence will be a tremendous asset to the Company.  Each of our Advisory Members brings specialized talents, skills and influence which will be instrumental in the Company achieving its goals of becoming a dominant global brand.  Having someone such as Dr. Gupta join our Advisory Board speaks volumes and reinforces our commitment to creating best in class products and being at the forefront in innovation in this rapidly evolving field.”

ABOUT TREE OF KNOWLEDGE

The Company produces and sells hemp-based cannabidiol (‘CBD”) products in certain jurisdictions in the United States, as well as in Europe, South America, Australia and China.  Cannabidiol/CBD is a natural constituent of hemp which is purported to contain wellness properties. TOK’s CBD product line contains EVR Premium Hemp Oil, which is an organically grown and handled, gluten-free, vegan, non-GMO, synergistic compound that is derived from U.S. Department of Agriculture (USDA) approved industrial hemp grown in the United States.  TOK currently offers several CBD products, which may be used in connection with the treatment of a number of ailments and for general wellness purposes.

For further information about TOK, please see the Company’s website at www.Evrcbd.com or contact the following:

Tree of Knowledge International Corp.

Michael Caridi, Chairman and CEO or                 Daniel Caridi

Tel:  +1 (917) 295-1374                                              Assistant to the Chairman

Michael@evrcbc.com                                                 +1(203) 969-5678
Daniel@evrcbd.com

Rahim Rajwani

Partner/Founder/Head of Compliance and Risk

Northbay Capital Partners Corp.

Suite 918-1030 West Georgia Street

Vancouver, BC V6E 2Y3

M: 604.376.8821

T: 604.628.2661

www.northbaycapitalpartners.com

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Source: www.fscwire.com

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna‘s annual general meeting of shareholders held on June 24, 2021 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Keep reading... Show less

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less